Fingolimod 0.5 mg

( DrugBank: Fingolimod / KEGG DRUG: Fingolimod )

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	8

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

trials per page:

Showing 1 to 8 of 8 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02373098 (ClinicalTrials.gov)	March 31, 2015	4/2/2015	Fingolimod Effect on Cytokine and Chemokine Levels	Effects of Fingolimod (Gilenya®) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sc ...	Relapsing Remitting Multiple Sclerosis	Drug: Fingolimod 0.5 mg	Novartis Pharmaceuticals	NULL	Completed	18 Years	65 Years	All	126	Phase 4	Turkey
2	NCT01941004 (ClinicalTrials.gov)	June 2014	9/9/2013	Safety and Efficacy of Fingolimod in MS Patients in China	A 12 Month Study, With a 6-month, Double-blind, Randomized, Placebo-controlled, Multi-center Paralle ...	Multiple Sclerosis (Relapsing Remitting)	Drug: fingolimod;Drug: Placebo (6mos) + open label fingolimod (6 mos)	Novartis Pharmaceuticals	NULL	Withdrawn	18 Years	50 Years	All	0	Phase 3	NULL
3	NCT01497262 (ClinicalTrials.gov)	February 2012	5/12/2011	Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis	A 4-month, Open-label, Multi-center Study to Explore the Safety and Tolerability of Fingolimod 0.5 m ...	Multiple Sclerosis	Drug: Fingolimod	Novartis Pharmaceuticals	NULL	Completed	18 Years	65 Years	All	162	Phase 3	Argentina;Brazil;Colombia;Jordan;Malaysia;Mexico;Panama;Peru;Costa Rica
4	NCT01534182 (ClinicalTrials.gov)	January 2012	8/2/2012	Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transi ...	A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcome ...	Relapsing Remitting Multiple Sclerosis	Drug: Fingolimod;Drug: Interferon beta - 1a (IFN);Drug: Glatiramer acetate (GA)	Novartis Pharmaceuticals	NULL	Completed	18 Years	65 Years	All	298	Phase 4	Russian Federation
5	NCT01281657 (ClinicalTrials.gov)	February 2011	19/1/2011	Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program	A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Ef ...	Multiple Sclerosis	Drug: fingolimod	Novartis	NULL	Completed	18 Years	N/A	Both	64	N/A	United States;Canada
6	NCT00662649 (ClinicalTrials.gov)	February 2008	17/4/2008	Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple S ...	An Extension of the 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-gr ...	Multiple Sclerosis	Drug: Fingolimod 0.5 mg;Drug: Fingolimod 1.25 mg	Novartis	NULL	Completed	20 Years	58 Years	All	920	Phase 3	Australia;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel ...
7	NCT00340834 (ClinicalTrials.gov)	May 2006	19/6/2006	Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optio ...	A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing ...	Multiple Sclerosis	Drug: Fingolimod 1.25 mg;Drug: Fingolimod 0.5 mg;Drug: Interferon ß-1a 30 µg	Novartis	NULL	Completed	18 Years	55 Years	All	1292	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Egypt;France;Germany;Greece;Hungary; ...
8	NCT00289978 (ClinicalTrials.gov)	January 2006	9/2/2006	Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis	A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparin ...	Relapsing-remitting Multiple Sclerosis	Drug: Fingolimod 1.25 mg;Drug: Fingolimod 0.5 mg;Drug: Placebo	Novartis	NULL	Completed	18 Years	55 Years	All	1272	Phase 3	Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Israel;Lithuania;Netherlands;P ...

First Previous1Next Last